Position in EXEL
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$1,304,969
+$276,296 QoQ
Shares Held
23,984
0.0% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#308
of 751 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sivia Capital Partners, LLC holds $6,325,939 across 12 Biotechnology names. EXEL ranks #2 (20.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
5,641 | $1,359,311 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
23,984 | $1,304,969 | |
| 3 | RPRX |
Royalty Pharma plc
|
13,561 | $760,365 | |
| 4 | INCY |
Incyte Corp
|
5,658 | $641,390 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
12,420 | $439,543 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
12,951 | $432,433 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,305 | $392,844 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
5,929 | $339,257 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,304,969 | 23,984 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $1,028,673 | 23,984 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,218,956 | 27,811 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $586,996 | 14,213 | Shares | Sole | 2025-10-20 | |
| 2025-03-31 | $428,198 | 11,598 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $314,218 | 9,436 | Shares | Sole | 2025-01-13 | |
| 2024-09-30 | $244,864 | 9,436 | Shares | Sole | 2024-10-11 | |
| 2024-06-30 | $212,026 | 9,436 | Shares | Sole | 2024-08-05 | |
| 2024-03-31 | $223,916 | 9,436 | Shares | Sole | 2024-04-19 | |
| No filing history on record for this holder in this stock. | ||||||